2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 3186

Foot Synovitis in Patients with Rheumatoid Arthritis in Apparent Remission Is Associated with Unstable Remission Status, Radiographic Progression and Worse Long-Term Functional Outcomes
Abstract Number: 3187

Predictors of Disease Relapse and Recapture of Remission Following Relapse in an Ontario Rheumatoid Arthritis Population
Abstract Number: 3188

Inhibition of Lymphatic Muscle Contraction By Lymphatic Endothelial iNOS Impairs Lymph Drainage from Arthritic Joints in TNF-Tg Mice and Is Prevented By Herbal Drugs
Abstract Number: 3189

Enhancement of Mitochondrial Biogenesis Inhibits Cell Proliferation and MMP-3/RANKL Secretion in Rheumatoid Arthritis Fibroblast-like Synovial Cells and Joint Destruction in Arthritis Model Mice
Abstract Number: 3190

Netrin-1 and Its Receptor Unc5b Are Novel Targets for the Treatment of Inflammatory Arthritis
Abstract Number: 3191

Siglec9 Suppresses Arthritis in Collagen-Induced Mice Model and Inhibits M1 Activation of RAW264.7 Macrophages
Abstract Number: 3192

KCa3.1 Ion Channel in the Pathogenesis of Rheumatoid Arthritis: KCa3.1-/- Mice Do Not Develop CIA
Abstract Number: 3193

Immunomodulatory and Antiviral Therapies in a Mouse Model of Chikungunya Viral Arthritis
Abstract Number: 3194

Oral to Subcutaneous Methotrexate Dose-Conversion Strategies in the Treatment of Rheumatoid Arthritis
Abstract Number: 3195

Circulating Micro-RNA Profiles in Responders to Adalimumab Plus Methotrexate Versus Methotrexate Alone: A Placebo-Controlled Clinical Trial
Abstract Number: 3196

Predictive Biomarkers for Response or Non-Response to MTX Monotherapy in Early RA
Abstract Number: 3197

Clinical Practice Experience in Rheumatoid Arthritis Patients Treated with Triple Therapy and Methotrexate-Tumor Necrosis Factor Inhibition Differs from That of Randomized Controlled Trials
Abstract Number: 3198

Treatment of Rheumatoid Arthritis with an Anti-Tumor Necrosis Factor Agent or Tocilizumab As First Biologic Therapy in a Global Comparative Observational Study
Abstract Number: 3199

In Rheumatoid Arthritis (RA) Patients, Retreatment with Rituximab (RTX) at Half Dose Does Not Alter Maintenance on Drug and Allows One Third Reduction of Cumulative Dose of Drug/Year: Data from the Autoimmunity and Rituximab (AIR) Registry
Abstract Number: 3200

Characterization of Early and Progressive Autoimmunity in Sjogrens Syndrome: The Incomplete Sjogrens Syndrome Model

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].